{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:13:25Z","timestamp":1788880405180,"version":"build-2803163510"},"reference-count":43,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"abstract":"\n Importance<\/jats:title>\n The respiratory syncytial virus (RSV) bivalent prefusion F protein vaccine (RSVpreF) administered during pregnancy has demonstrated efficacy in protecting infants against early-life RSV disease in the pivotal clinical trial.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To conduct a systematic review and meta-analysis to synthesize real-world evidence on the effectiveness of RSVpreF in preventing RSV-associated lower respiratory tract infection (LRTI) in infants.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Scopus, and Europe PMC were searched from January 1, 2020, through January 30, 2026.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n A total of 1144 studies were initially identified. Eligible were nonrandomized studies reporting the effectiveness of RSVpreF vaccine in pregnancy in the prevention of RSV-associated LRTI in infants.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n All studies were screened independently by 2 reviewers. Data were extracted on RSV-associated outcomes among infants born to women who received RSVpreF vaccination during pregnancy and infants born to unvaccinated women.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was RSV-associated LRTI hospitalization. Odds ratios (ORs) were pooled using random-effects meta-analysis with the Hartung-Knapp adjustment and Sidik-Jonkman estimator. Vaccine effectiveness against RSV-associated LRTI hospitalization was calculated as (1\u2009\u2212\u2009OR)\u2009\u00d7\u2009100% and assessed in infants from birth to age 3 months and from birth to 6 months, separately. The limited available data precluded meta-analysis of effectiveness against the secondary outcomes of RSV-associated emergency department visits, intensive care unit admissions, and death.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 7 studies were included, comprising 7112 infants, of whom 2684 were born to vaccinated mothers. The studies collected data from January 2024 through April 2025 from Argentina, the UK, and the US. Pooled vaccine effectiveness against RSV-associated LRTI hospitalization was 82% (95% CI, 81%-82%; 3 studies, 4397 participants;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u20090%) in infants from birth to 3 months and 78% (95% CI, 70%-84%; 6 studies, 3008 participants;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200918.7%) in infants from birth to 6 months, when mothers were vaccinated 14 days or more before delivery.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this systematic review and meta-analysis suggest that postimplementation data support the effectiveness of RSVpreF in pregnancy for the prevention of RSV-associated LRTI hospitalization during the first 6 months of life. The results support the introduction of RSVpreF into routine antenatal immunization programs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2026.4074","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:00:44Z","timestamp":1788879644000},"source":"Crossref","is-referenced-by-count":0,"title":["RSV Bivalent Prefusion F Protein Vaccine in Pregnancy and Protection Against RSV-Associated Illness in Infants"],"prefix":"10.1001","author":[{"given":"Rabab","family":"Batool","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"},{"name":"Departments of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Laboratory of Infection and Virology, Beijing Pediatric Research Institute, Beijing Children\u2019s Hospital, National Center for Children\u2019s Health, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Obeid","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"},{"name":"Departments of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias R.","family":"Kollmann","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"},{"name":"Departments of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Departments of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Langley","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"},{"name":"Departments of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal M.","family":"Lavoie","sequence":"additional","affiliation":[{"name":"British Columbia Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"},{"name":"Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa","family":"Abu-Raya","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada"},{"name":"Departments of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Departments of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"10340","key":"poi260057r1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"poi260057r2","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1038\/s41598-021-88524-w","article-title":"Population-based serology reveals risk factors for RSV infection in children younger than 5 years.","volume":"11","author":"Andeweg","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"poi260057r4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12519-025-00926-2","article-title":"Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.","volume":"21","author":"Goh","year":"2025","journal-title":"World J Pediatr"},{"issue":"5","key":"poi260057r5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamapediatrics.2026.0035","article-title":"RSV antibody prophylaxis needs for extremely preterm infants in their second RSV season.","volume":"180","author":"Vi\u00f1eta Paramo","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"7","key":"poi260057r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.19410","article-title":"RSV hospital admissions during the first 2 seasons among children with chronic medical conditions.","volume":"8","author":"Vi\u00f1eta Paramo","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"poi260057r7","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","article-title":"Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.","volume":"13","author":"Resch","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"poi260057r8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14787210.2025.2481908","article-title":"Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children.","volume":"23","author":"Carbonell-Estrany","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"poi260057r13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis.","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"13","key":"poi260057r14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants.","volume":"393","author":"Zar","year":"2025","journal-title":"N Engl J Med"},{"issue":"16","key":"poi260057r16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"poi260057r17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(26)00134-3","article-title":"A national program of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalization in infants until age 6 months in the UK: a multicenter, prospective, test-negative, case-control study.","author":"O\u2019Hagan","year":"2026","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"poi260057r18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across 2 respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study.","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"poi260057r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model.","volume":"11","author":"Baral","year":"2021","journal-title":"BMJ Open"},{"issue":"2","key":"poi260057r20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial.","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet Gynecol"},{"key":"poi260057r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101296","article-title":"Impact and effectiveness of RSV maternal immunization on infant hospitalizations in Buenos Aires: a hospital-based, multicentre, retrospective surveillance cohort study.","volume":"52","author":"Razzini","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"4","key":"poi260057r22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1473-3099(25)00624-3","article-title":"Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case-control study and cohort analysis.","volume":"26","author":"McLachlan","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"poi260057r23","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalization in infants during the 2024 RSV season in Argentina (BERNI study): a multicenter, retrospective, test-negative, case-control study.","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"poi260057r24","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"poi260057r25","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"11","key":"poi260057r26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"9","key":"poi260057r27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2352-4642(25)00155-5","article-title":"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalization in infants in the UK: results of a multicenter, test-negative, case-control study.","volume":"9","author":"Williams","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"poi260057r28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/INF.0000000000004878","article-title":"Maternal immunization with RSVpreF vaccine: effectiveness in preventing respiratory syncytial virus\u2013associated hospitalizations in infants under 6 months in Argentina: multicenter case-control study.","volume":"44","author":"Gentile","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"poi260057r29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamapediatrics.2025.5778","article-title":"Effectiveness and impact of maternal RSV immunization and nirsevimab on medically attended RSV in US children.","volume":"180","author":"Moline","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"6","key":"poi260057r30","article-title":"Evaluation of the effectiveness of the respiratory syncytial virus vaccine in children under 6 months of age in C\u00f3rdoba, Argentina.","volume":"123","author":"Scruzzi","year":"2025","journal-title":"Arch Argent Pediatr"},{"issue":"5","key":"poi260057r31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants.","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"poi260057r32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016131","article-title":"Efficacy and safety of respiratory syncytial virus vaccines.","volume":"9","author":"Saif-Ur-Rahman","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"poi260057r33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12026-025-09732-4","article-title":"Maternal RSV vaccine: a systematic review and meta-analysis of immunogenicity and perinatal safety.","volume":"73","author":"Saad","year":"2025","journal-title":"Immunol Res"},{"issue":"25","key":"poi260057r34","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1016\/j.vaccine.2017.04.035","article-title":"Case-control vaccine effectiveness studies: data collection, analysis and reporting results.","volume":"35","author":"Verani","year":"2017","journal-title":"Vaccine"},{"issue":"32","key":"poi260057r35","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/j.vaccine.2022.06.034","article-title":"Biological factors that may impair transplacental transfer of RSV antibodies: implications for maternal immunization policy and research priorities for low- and middle-income countries.","volume":"40","author":"Atwell","year":"2022","journal-title":"Vaccine"},{"issue":"32","key":"poi260057r37","doi-asserted-by":"publisher","first-page":"E1114","DOI":"10.1503\/cmaj.240780","article-title":"Nirsevimab to reduce infant morbidity from respiratory syncytial virus.","volume":"196","author":"Abu-Raya","year":"2024","journal-title":"CMAJ"},{"issue":"388","key":"poi260057r38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"poi260057r39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.","volume":"14","author":"Brady","year":"2023","journal-title":"Front Immunol"},{"issue":"26","key":"poi260057r40","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1016\/j.cell.2022.11.012","article-title":"Antibody effector functions are associated with protection from respiratory syncytial virus.","volume":"185","author":"Bartsch","year":"2022","journal-title":"Cell"},{"issue":"5","key":"poi260057r41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants.","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"poi260057r42","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf695.008","article-title":"225. The immunology and safety of maternal RSV vaccination, infant nirsevimab immunization, or both products: interim analysis of a randomized clinical trial.","volume":"13","author":"Rostad","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"poi260057r43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.44679","article-title":"Nirsevimab prophylaxis and respiratory syncytial virus hospitalizations among infants.","volume":"8","author":"Cocchi","year":"2025","journal-title":"JAMA Netw Open"},{"key":"poi260057r3","unstructured":"World Health Organization. Respiratory Syncytial Virus (RSV). Accessed January 14, 2026. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/respiratory-syncytial-virus-(rsv)"},{"key":"poi260057r9","unstructured":"GAVI The Vaccine Alliance. Eligibility policy. Accessed December 31, 2025. https:\/\/www.gavi.org\/types-support\/sustainability\/eligibility"},{"key":"poi260057r10","unstructured":"Sanofi. Sanofi receives marketing authorization for Beyfortus in India to protect infants and children against respiratory syncytial virus (RSV). Published online August 31, 2024. Accessed July 10, 2026. https:\/\/www.sanofi.com\/assets\/countries\/india\/docs\/Media\/press-releases\/2024\/sanofi-receives-marketing-authorization-for-beyfortus-in-india-to-protect-infants-and-children-against-respiratory-syncytial-virus-rsv.pdf"},{"key":"poi260057r11","unstructured":"World Health Organization. WHO Global Market Study on respiratory syncytial virus immunization products. Published online November 2024. Accessed June 4, 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mi4a\/who-global-market-study-on-rsv-immunization-products_november-2024.pdf?sfvrsn=e6ff42a9_3&download=true"},{"key":"poi260057r12","unstructured":"Access to Medicine Foundation. Recent advancements in unlocking access to RSV prevention for children in LMICs. Accessed January 14, 2026. https:\/\/accesstomedicinefoundation.org\/insights-resources\/access-insights\/recent-advancements-in-unlocking-access-to-rsv-prevention-for-children-in-lmics"},{"key":"poi260057r15","unstructured":"Merck. FDA approves Merck\u2019s Enflonsia (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season. Accessed July 10, 2026. https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir\/"},{"key":"poi260057r36","doi-asserted-by":"crossref","unstructured":"Jasset? MOJ, Zapana? PAL, Bahadir? Z, . Longer interval between maternal RSV vaccination and birth increases placental transfer efficiency.? medRxiv. 2024 doi:10.1101\/2024.07.14.24310390","DOI":"10.1101\/2024.07.14.24310390"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2853476\/jamapediatrics_batool_2026_oi_260057_1787587833.81988.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:00:47Z","timestamp":1788879647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2853476"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2026.4074","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}